Centrophenoxine is a 1950s memory drug used abroad for age-related decline. Older animal and small human studies hint at modest memory gains and reduced brain "age pigment," but proof of meaningful or lifespan benefit stays thin and unconfirmed. Generally well tolerated short-term; long-term safety unknown, and many products sold are mislabeled. (Full Review)

Protocol

Dose

Start 250 mg/day

Titrate up only if tolerated; trial range ~250–1,000 mg/day

Timing

Morning & midday

Avoid late-afternoon or evening dosing to prevent sleep disruption

Schedule

Split dosing

Preferred over a single large dose to smooth effects and reduce peak side effects

Time to effect

Memory effects

Weeks to months

Memory effects seen in trials emerged over weeks to months of continuous use

Acute effects

Hours to days

Acute stimulant-like and cognitive effects may be noticed within hours to days

Benefits

Low: Memory support in older adults; reduction of lipofuscin

Speculative: Lifespan extension; neuroprotection in neurodegenerative disease; general anti-oxidant and cellular "rejuvenation" effects

Contraindications

Pregnancy or breastfeeding

Uncontrolled seizure disorders (epilepsy)

Unstable bipolar disorder or severe anxiety

Known hypersensitivity to the compound

Key Interactions

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine)

Other cholinergic supplements (alpha-GPC, citicoline, DMAE, huperzine A)

Stimulants (caffeine, methylphenidate, amphetamines)

Antidepressants and mood-acting drugs

OTC anticholinergics (diphenhydramine, doxylamine)

Parkinson's disease with involuntary movements

Risk & Side Effects

Medium: Cholinergic overstimulation effects; product quality and mislabeling hazard

Low: Excitation, agitation, and sleep disruption

Speculative: Theoretical concern from the pCPA moiety and DMAE in pregnancy; long-term and cumulative safety unknowns

Monitoring

Marker	Target	Why
Blood pressure & resting heart rate	BP <120/80 mmHg; HR 60–80 bpm	Detects stimulant-related cardiovascular effects
Comprehensive metabolic panel (CMP)	ALT/AST <25 U/L; fasting glucose 75–85 mg/dL; eGFR >90 mL/min/1.73m²	General safety screen for long-term users

Cadence: Tolerability check at ~1–2 weeks after starting or any dose increase; cognitive and side-effect review at ~8–12 weeks; periodic review every 6–12 months for long-term use

Qualitative Assessment

Memory and recall
Mental clarity and focus
Energy and mood
Sleep
Headache or jaw tension

Centrophenoxine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment